
Multiple Myeloma
Latest News
Latest Videos

CME Content
More News





Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.


















Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses current and emerging targets for immunotherapy in the treatment of patients with multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Peter Voorhees, MD, discusses the clinical potential of adding daratumumab to bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.














































